Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-benzylcysteine is a synthetic derivative of the amino acid cysteine, classified as an L-cysteine-S-conjugate and used primarily in research and experimental applications. It is a small molecule with antioxidant properties, widely utilized as a building block in peptide synthesis, drug discovery, and bioconjugation processes[1][2][4][5]. In biological studies, S-benzylcysteine has demonstrated cytotoxic activity against certain cancer cell lines by inducing G2-phase cell cycle arrest and apoptosis through activation of mitochondrial-dependent caspase cascades involving the p53 pathway[6]. Its unique chemical structure makes it valuable for developing new therapeutics targeting diseases related to oxidative stress, inflammation, and potentially cancer. Additionally, it finds use in cosmetics for its skin-protective benefits and in agricultural research for enhancing plant resistance to stress[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-benzylcysteine.